Full-Time

Warehouse & Materials Contractor

Abzena

Abzena

201-500 employees

CDMO for complex biologics and ADCs

No salary listed

Bristol, PA, USA

In Person

Bachelor's, Associate's

Category
Warehouse & Fulfillment (2)
,
Required Skills
ERP
Supply Chain Management
GMP

Get referred to Abzena

See people who can refer or advise you

Requirements
  • A high school diploma or equivalent is required.
  • A minimum of 5 years of experience in warehouse operations, materials management, inventory control, logistics, supply chain, manufacturing support, or a related function is required.
  • Experience using an enterprise resource planning, warehouse management, or inventory management system to execute material transactions and maintain inventory records is required.
  • Working knowledge of Good Manufacturing Practices, Good Distribution Practices, data integrity, inventory control, material status control, and warehouse documentation practices is required.
  • Demonstrated ability to perform cycle counts, inventory reconciliation, material movements, receiving, staging, and storage activities accurately is required.
  • Ability to maintain accurate physical and electronic records is required.
  • Ability to identify discrepancies, communicate issues promptly, and support structured problem resolution is required.
  • Ability to work independently, follow controlled procedures, and manage changing priorities in a fast-paced Good Manufacturing Practice environment is required.
  • Ability to work effectively across Materials Management, Manufacturing, Quality, Quality Control, and Supply Chain is required.
  • Ability to complete defined project work independently, track actions and deliverables, and communicate progress against deadlines is required.
  • Ability to work in warehouse, receiving, manufacturing support, cold-storage, and office environments is required.
  • Ability to stand, walk, bend, reach, and perform material-handling activities for extended periods is required.
  • Ability to wear required personal protective equipment and follow site safety requirements is required.
  • Ability to lift and move materials in accordance with site safety requirements and established lifting limits is required.
  • Ability to work at a computer and use enterprise resource planning, inventory, and documentation systems is required.
Responsibilities
  • Execute assigned Materials Management projects against defined scope, priorities, milestones, and completion dates.
  • Maintain project trackers and provide routine status updates on progress, open actions, risks, constraints, and completed deliverables.
  • Own assigned inventory accuracy and reconciliation workstreams, including physical-to-system reconciliation and closure of identified discrepancies.
  • Execute enterprise resource planning and material master data cleanup activities, including review and correction of inventory records, Bills of Materials, Material Requests, Shop Orders, storage locations, and other assigned master data.
  • Support warehouse optimization projects, including location rationalization, material segregation, labeling, inventory disposition support, and improvement of material flow.
  • Execute assigned third-party logistics transition activities, including inventory preparation, reconciliation, transfer documentation, physical movement, post-transfer verification, and closure of transfer discrepancies.
  • Support documentation remediation projects by reviewing, organizing, correcting, and closing assigned Materials Management records in accordance with Good Manufacturing Practice and Good Distribution Practice requirements.
  • Identify project risks or barriers that could affect schedule, compliance, inventory accuracy, or operational continuity and escalate them promptly to the project owner or Materials Management leadership.
  • Provide documented evidence of project completion and support handoff of completed processes, records, or improvements to the permanent Materials Management team.
  • Execute day-to-day receiving, warehousing, storage, staging, picking, issuing, transfer, and inventory control activities in accordance with approved standard operating procedures and Good Manufacturing Practice/Good Distribution Practice requirements.
  • Receive incoming materials and verify shipment condition, quantities, labels, documentation, and applicable storage requirements before staging or storage.
  • Maintain appropriate material status and segregation, including quarantine, released, rejected, returned, expired, and other controlled inventory statuses as applicable.
  • Perform accurate inventory movements and transactions in the IFS enterprise resource planning system, including receipts, transfers, issues, adjustments, and other authorized inventory transactions.
  • Support cycle counts, physical inventory verification, reconciliation, and investigation of discrepancies between physical inventory, enterprise resource planning records, and supporting documentation.
  • Organize, label, stage, and store materials to support safe handling, traceability, inventory accuracy, and efficient material flow.
  • Support temperature-sensitive and controlled-storage materials by following defined handling, storage, transfer, and monitoring requirements.
  • Maintain complete and contemporaneous warehouse records, logbooks, labels, forms, and electronic transactions in accordance with Good Distribution Practice and data integrity expectations.
  • Review and support correction of material master data, Bills of Materials, Material Requests, Shop Orders, and related inventory records to improve transactional accuracy.
  • Support SKU and inventory rationalization, obsolete or excess inventory review, location cleanup, and other inventory optimization activities.
  • Identify material, documentation, labeling, storage, or system discrepancies and promptly escalate issues in accordance with site procedures.
  • Support deviation investigations, corrective actions, and continuous improvement activities related to warehouse execution, inventory accuracy, and materials management, as assigned.
  • Assist with preparation, reconciliation, documentation, and physical transfer of inventory to approved third-party logistics providers, including SciSafe.
  • Verify inventory quantities and records before, during, and after external warehouse transfers to maintain traceability and accurate chain of custody.
  • Coordinate with Manufacturing and other internal customers to stage and deliver materials in support of planned Good Manufacturing Practice operations.
  • Maintain warehouse areas in a clean, organized, inspection-ready condition and follow all site environmental, health, and safety, personal protective equipment, material-handling, and housekeeping requirements.
  • Safely use pallet jacks, carts, and other approved material-handling equipment when trained and authorized.
  • Participate in warehouse process standardization, work instruction development, and operational improvement activities.
  • Perform other Materials Management and warehouse activities as assigned.
Desired Qualifications
  • Experience in a Good Manufacturing Practice-regulated pharmaceutical, biotechnology, medical device, or other regulated manufacturing environment is strongly preferred.
  • Experience with IFS enterprise resource planning, Bills of Materials, Shop Orders, Material Requests, third-party logistics transfers, cold-chain materials, barcode/radio-frequency scanning, or powered material-handling equipment is preferred.
  • Experience supporting inventory remediation, warehouse optimization, enterprise resource planning cleanup, third-party logistics transitions, or similar operational improvement projects is preferred.

Abzena is a CDMO that provides integrated services for complex biologics and bioconjugates, including antibody-drug conjugates (ADCs). It supports projects from antibody discovery through GMP manufacturing for clinical trials and commercial supply, using its in-house platforms and expertise. It differentiates itself with end-to-end development and manufacturing capabilities, supported by proprietary technologies like ThioBridge and Composite Human Antibody, and global facilities in San Diego, Bristol, and Cambridge. Its goal is to help biologics programs progress efficiently from discovery to market by offering specialized, partnered development and manufacturing services and potential licensing of its technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Babraham, United Kingdom

Founded

2001

Get referred to Abzena

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 2025 CEO Geoffrey Glass unified strategy after chairman tenure.
  • September 2025 GS knockout launches expand standalone and GMP cell-line revenue.
  • 2026 Tasrif and Promatix projects show customer demand for Abzena platforms.

What critics are saying

  • Lonza, WuXi, and Samsung Biologics outscale Abzena on global capacity.
  • Abzena's 2025 class-action settlement keeps employment claims visible to candidates.
  • If ADC and AOC programs slow, expanded CDMO capacity sits underutilized.

What makes Abzena unique

  • Abzena owns integrated discovery-to-GMP workflows for complex biologics and bioconjugates.
  • ThioBridge and AbZelectPRO KO platforms speed ADC and afucosylated protein programs.
  • Frost & Sullivan named Abzena a 2026 leader for ADC CDMOs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Abzena
Jul 15th, 2026
Outsourced Pharma capability Update - Cell Line Development June 2026.

Outsourced Pharma capability Update - Cell Line Development June 2026. Early cell line decisions define everything that comes after: yield, stability, manufacturability, and timelines. That's why Abzena PLC presented at the Outsourced Pharma Capabilities Update on June 16th, which is focused on Cell Line Development strategies. Abzena's VP & Scientific Leader of Cell Line Development, John E. Gill IV, presented a talk on "Integrated Cell Line Development: Manufacturability to GMP-Ready by Design." John broke down how a truly integrated approach, one built with GMP readiness and manufacturability in mind from day one, changes the trajectory of complex biologic programs. The result: - Accelerated timelines to GMP - Reduced downstream risk - Cell lines engineered to meet GMP standards, not retrofitted to them - A smoother, faster path from discovery to clinical & commercial manufacturing When GMP readiness is designed in from the start, not added later, programs don't stall. They move forward faster.

Abzena
Mar 17th, 2026
Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations.

Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations. Abzena is recognized as a technology-forward, innovative CDMO in the Frost radar(tm): ADC contract development and manufacturing report, 2025. In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research analysts Frost & Sullivan, an independent firm, evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth. As the author of the report, Unmesh Lal, VP of Healthcare & Life Sciences at Frost & Sullivan, shared, "With deep analytical expertise, flexible licensing models, and a dual US-UK footprint, Abzena combines scientific rigor with commercial agility. Its 'grow-with-the-client' strategy is converting early-stage partnerships into long-term manufacturing relationships, solidifying its position as a premier end-to-end CDMO for complex biologics." * How Abzena's proprietary ThioBridge(R) site-specific conjugation platform improves the design & delivery of ADCs. * How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs. * How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors * How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.

Clinical Research News
Sep 16th, 2025
Abzena Enhances AbZelectPRO(TM) Cell Line Offering with New GS Knockout Platforms

Abzena enhances abzelectpro(tm) cell line offering with new GS knockout platforms san diego, CA - september 15, 2025 - abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its abzelectpro(tm) cell line development (CLD) platform with the launch of two next-generation glutamine synthetase ("GS") knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Bio-IT World
Jul 22nd, 2025
Appointment; Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

San Diego, CA - July 22, 2025 - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately.

PR Newswire
May 15th, 2025
Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation.Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster."Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth